INBX (Inhibrx Biosciences) Common Stock : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Inhibrx Biosciences Common Stock?

Inhibrx Biosciences's quarterly common stock stayed the same from Jun. 2024 ($0.00 Mil) to Sep. 2024 ($0.00 Mil) and stayed the same from Sep. 2024 ($0.00 Mil) to Dec. 2024 ($0.00 Mil).

Inhibrx Biosciences's annual common stock increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.01 Mil) but then declined from Dec. 2023 ($0.01 Mil) to Dec. 2024 ($0.00 Mil).

Inhibrx Biosciences Common Stock Historical Data

The historical data trend for Inhibrx Biosciences's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhibrx Biosciences Common Stock Chart

Inhibrx Biosciences Annual Data

Trend

Dec22

Dec23

Dec24

Common Stock

0.01

Inhibrx Biosciences Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Common Stock	Get a 7-Day Free Trial				0.01	-	-	-	-

Inhibrx Biosciences Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Inhibrx Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibrx Biosciences Inc (NAS:INBX) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

11025 N. Torrey Pines Road, Suite 140, La Jolla, CA, USA, 92037

Website

https://www.inhibrx.com

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.